Jan Tesarik 1,2,5, André Hazout 3, Raquel Mendoza-Tesarik 1, Nicolas Mendoza 1 and Carmen Mendoza 1,4
|
|
- Edgar Neal
- 6 years ago
- Views:
Transcription
1 Human Reproduction Vol.21, No.10 pp , 2006 Advance Access publication August 22, doi: /humrep/del173 Beneficial effect of luteal-phase administration on embryo implantation after ICSI in both - and antagonist-treated ovarian stimulation cycles Jan Tesarik 1,2,5, André Hazout 3, Raquel Mendoza-Tesarik 1, Nicolas Mendoza 1 and Carmen Mendoza 1,4 1 MAR&Gen, Molecular Assisted Reproduction and Genetics, Granada, Spain, 2 Laboratoire d Eylau, 3 ARCEFAR, Paris, France and 4 Department of Biochemistry and Molecular Biology, Faculty of Sciences, University of Granada, Campus Universitario Funetenueva, Granada, Spain 5 To whom correspondence should be addressed at: cmendoza@ugr.es BACKGROUND: was recently suggested as a novel luteal-phase support that may act at different levels, including the pituitary gonadotrophs, the endometrium and the embryo itself. This prospective randomized study evaluates the effect of administered in the luteal phase on ICSI outcomes in both - and GnRH antagonist-treated ovarian stimulation protocols. METHODS: Six hundred women about to undergo ovarian stimulation for ICSI (300 using a long protocol and 300 using a GnRH antagonist protocol) were enrolled in this study. Patients treated with each of these two protocols were randomly assigned to receive a single injection of or placebo 6 days after ICSI. Implantation and live birth rates were the primary outcomes. RESULTS: Administration of 0.1 mg of triptorelin on day 6 after ICSI led to a significant improvement of implantation and live birth rates after ICSI as compared with placebo. In GnRH antagonist-treated ovarian stimulation cycles, luteal-phase also increased ongoing pregnancy rate. Moreover, luteal-phase GnRH agonist administration increased luteal-phase serum HCG, estradiol and progesterone concentrations in both ovarian stimulation regimens. CONCLUSIONS: administration enhances ICSI clinical outcomes after - and GnRH antagonist-treated ovarian stimulation cycles, possibly by a combination of effects on the embryo and the corpus luteum. Key words: corpus luteum function/embryo developmental potential//gnrh antagonist/luteal-phase support Introduction deficiency is a common problem in current assisted reproduction techniques (ARTs) and has been described in cycles using pituitary down-regulation with a as well as in those using GnRH antagonists (Macklon and Fauser, 2000; Pritts and Atwood, 2002; Beckers et al., 2003; Kolibianakis et al., 2003). To cope with this problem, different regimens of luteal-phase support were suggested (reviewed in Pritts and Atwood, 2002). Most of these regimens involve different application forms and doses of three therapeutic agents, HCG, vaginal or intramuscular progesterone and oral estradiol (E 2 ) (Pritts and Atwood, 2002). Some recent data, however, have suggested a beneficial effect of GnRH agonist administered in the luteal phase on ART outcomes (Tesarik et al., 2004; Pirard et al., 2005). The mechanism of the presumed beneficial effect of lutealphase administration is not clear and may be due to the drug action at multiple levels. It was hypothesized that may support the corpus luteum by stimulating the secretion of LH by pituitary gonadotroph cells or by acting directly on the endometrium through the locally expressed GnRH receptors (Pirard et al., 2005). However, the administration of a single dose of in the luteal phase was also shown to increase pregnancy, implantation, delivery and birth rates in recipients of donated oocytes in whom ovulation was suppressed and the corpus luteum was thus absent, suggesting a direct effect of on the embryo (Tesarik et al., 2004). To help clarify the mechanism of action in the luteal phase, this prospective randomized study evaluates the effect of luteal-phase administration on ICSI outcomes in the two most currently used ovarian stimulation protocols using, respectively, and GnRH antagonist for the prevention of a premature LH surge. Implantation 2572 The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 for luteal-phase support and live birth rates were the main outcome measures. Clinical pregnancy and ongoing pregnancy rates and luteal-phase serum concentrations of HCG (in conception cycles), LH and progesterone were secondary outcome measures. Materials and methods Study design and power calculation This prospectively randomized study was conducted between September 2003 and September It involves 600 infertile couples treated by ICSI and given two different protocols of ovarian stimulation, one using started in the luteal phase of the preceding cycle for pituitary down-regulation (300 couples) and the other using a GnRH antagonist for the prevention of a premature LH surge (300 couples). Patients to be treated by each of the two protocols were randomly assigned to two groups. In one group, women were given a single dose of 6 days after ICSI (3 days after embryo transfer). Women in the other group received placebo at the same time after ICSI. The decision of which couples would be treated by each of the two different ovarian stimulation protocols was subjective, and the study is thus not randomized as to comparison of ICSI outcomes with ovarian stimulation protocols using and GnRH antagonist, respectively, and the results can only serve to evaluate the usefulness of luteal-phase administration in each of the two protocols. Implantation and live birth rates were chosen as the main outcome measures. On the basis of previously published data (Tesarik et al., 2004) showing that the administration of 6 days after ICSI to recipients of donated oocytes increases implantation rate from 24.7% to 36.2%, it was hypothesized that a similar increase can be achieved with this method in ICSI patients undergoing ovarian stimulation. Assuming a significance level of 0.05 and a power of 0.80, it was calculated that some 100 treatment cycles were needed in each branch to detect this increase. It was decided to increase the number of cycles enrolled in each group to 150 to obtain a better chance to detect significant differences in some of the secondary outcome measures of this study; these were pregnancy and delivery rates, and luteal-phase serum concentrations of HCG (in conception cycles), LH and progesterone. The study protocol was approved by a competent institutional review board, and all participants signed an informed consent. Randomization protocol Couples selected for an ICSI attempt using each of the two ovarian stimulation protocols were randomized between a luteal-phase GnRH agonist group and a placebo group. Randomization was done with the use of a computer-generated randomization list. Sealed envelopes with treatment allocation instructions were opened on the day of embryo transfer by a nurse who assigned participants to their groups. The doctor and the biological team performing the ART were blinded to group assignment. Participants Six hundred infertile couples were enrolled in this study. Exclusion criteria were female age of >40 years and non-obstructive azoospermia requiring testicular sperm retrieval. Three hundred couples were assigned to an ovarian stimulation protocol using long and 300 to a protocol using GnRH antagonist. The decision between each of these two protocols was subjective and depended on the clinical context. Usually, the GnRH antagonist protocol was chosen in women presenting symptoms of polycystic ovaries and in those with a history of ovarian hyperstimulation syndrome (OHSS), but also in some women with expected good ovarian response without these features with the aim to reduce treatment cost and patient discomfort. The protocol was mostly, but not exclusively, used in women with expected normal or low ovarian response. Ovarian stimulation Long protocol Pituitary down-regulation was achieved with the use of daily injections of 0.1 mg of triptorelin (Decapeptyl 0.1 mg; Ipsen Pharma, Barcelona, Spain) starting in the luteal phase of the cycle preceding ovarian stimulation and reduced to 0.05 mg daily dose from the first day of vaginal bleeding. The gonadotrophin therapy was started 2 7 days after the beginning of the bleeding. This therapy was carried out with the use of recombinant human FSH (Puregon; Organon, Oss, The Netherlands or Gonal F; Serono, Rome, Italy) and HMG (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK). The doses of FSH and HMG were continuously adapted according to serum concentrations of E 2 and LH and to the dynamics of ovarian follicular growth as described (Tesarik and Mendoza, 2002) with the aim to maintain serum LH concentration in the range of IU l 1 throughout the stimulation period. Ovulation was induced with 250 μg of human recombinant HCG (Ovitrelle, Serono) when at least three follicles reached a mean diameter of 18 mm. The treatment with triptorelin was stopped on the day of HCG administration (last triptorelin injection on the day preceding HCG administration). GnRH antagonist protocol Recombinant human FSH and HMG administration was started on day 2 of menstrual bleeding following withdrawal of a contraceptive pill (Tri-Minulet; Wyeth Lederle, Madrid, Spain) administered during the cycle preceding ovarian stimulation. The doses of FSH and HMG were continuously adapted according to serum concentrations of E 2 and LH and to the dynamics of ovarian follicular growth in the same way as in the long protocol (discussed above). GnRH antagonist (Orgalutran; Organon or Cetrotide; Serono) was started on day 5 of gonadotrophin therapy and continued, at a daily dose of 0.25 mg, until at least three follicles reached a diameter of 18 mm when ovulation was induced with 250 μg of human recombinant HCG (Ovitrelle). ARTs Mature (metaphase II) oocytes were incubated at 37 C in G-FERT medium (Vitrolife, Göteborg, Sweden) equilibrated with 6% CO 2 in air for 3 6 h. They were then freed from the cumulus oophorus and corona radiata cells, subjected to ICSI as described (Tesarik and Mendoza, 2002) and incubated in G1 medium (Vitrolife) under the same gas phase. Fertilization was assessed h after ICSI. Zygotes were scored as having good morphology or poor morphology (see section Embryo selection for transfer ). After a medium change, embryos were cultured further in G1 medium until day 3 after ICSI with a medium change every day. At the time of medium change on day 2, embryo quality was assessed again (see section Embryo selection for transfer ). Embryo transfer was performed 3 days after ICSI with the use of K-JETS-7019-SIVF embryo transfer set (Cook, Queensland, Australia) and under transabdominal ultrasound guidance. One to three embryos were transferred in each cycle. If suitable, supernumerary embryos were frozen for later transfer. This study, however, only deals with fresh embryo transfers. Embryo selection for transfer Zygotes were evaluated according to criteria based on the assessment of the number and distribution of nucleolar precursor bodies in the pronuclei as described previously (Tesarik and Greco, 1999). The 2573
3 J.Tesarik et al. scoring system was simplified by grouping together all abnormal patterns (Tesarik et al., 2000), so as all zygotes were allocated to one of two groups good-morphology zygotes and poor-morphology zygotes. Cleaving embryos were evaluated twice, first at the time of medium change 2 days after ICSI and second min before transfer to the uterus 3 days after ICSI as described (Tesarik and Greco, 1999). Briefly, embryos that had more than three cells 2 days after ICSI and more than 6 cells 3 days after ICSI, that showed <10% of their space occupied by cell fragments and that developed from good-morphology zygotes were considered to have good morphology and were selected for transfer where available. supplementation Irrespective of whether was used as luteal-phase support or not, all women were given 4 mg of E 2 valerate (Progynova; Schering, Madrid, Spain) daily and 400 mg of vaginal micronized progesterone (Utrogestan; Laboratoires Besins-Iscovesco, Paris, France) daily from the day of oocyte recovery for 17 days. In addition, all women received an injection of 250 μg of human recombinant HCG (Ovitrelle) on the day of embryo transfer. Hormone assays Serum concentrations of 17β-E 2, progesterone and β-hcg were determined with the use of commercial enzyme immunoassay kits (Diagnostic Product Corporation, Los Angeles, CA, USA). The intraand inter-assay coefficients of variation (CVs) were, respectively, 3.8 and 5.6% for E 2, 3.7 and 4.0% for progesterone, and 3.5 and 4.1% for β-hcg. All measurements were taken according to the manufacturer s instructions. Statistics Differences between groups were assessed by two-tailed χ 2 -test with Yates correction or Fisher s exact test for categorical variables, and by Mann Whitney U-test or Welch t-test for continuous variables. The level of significance was set to P < Efficacy analyses were performed on an intention-to-treat (ITT) basis as appropriate, taking into account all randomized patients. Multidimensional statistics were performed using multivariate logistic regression analysis. All analyses were performed using the Statistica 5.0 package (Statsoft Version 5.1, Hamburg, Germany). Results Patient flow through the trial The trial was performed according to CONSORT guidelines. Infertile couples continued to be assessed for eligibility study until 150 patients were eligible in both the treatment and the placebo arm in each of the two ovarian stimulation protocols. Among the patients in whom the long ovarian stimulation protocol was indicated, 13 did not meet the inclusion criteria and eight refused to participate in the study (Figure 1A). Among the patients in whom the GnRH antagonist ovarian stimulation protocol was indicated, 11 did not meet the inclusion criteria and seven refused to participate in the study (Figure 1B). Among the patients treated with the long stimulation protocol and assigned to the luteal-phase GnRH agonist group, two discontinued the ovarian stimulation and three had no embryos for transfer. Of the remaining 145 patients who received allocated intervention, one was lost to 2574 follow-up, three were excluded from analysis because of failure to follow correctly the protocol of luteal-phase examinations, and 141 terminated the study and were analysed (Figure 1A). Among the patients treated with the long stimulation protocol and assigned to the placebo group, two were cancelled because of inadequate response to ovarian stimulation and five had no embryos for transfer. Of the remaining 143 patients who received allocated intervention, one was excluded from analysis because of failure to follow correctly the protocol of luteal-phase examinations, and 142 terminated the study and were analysed (Figure 1A). Among the patients treated with the GnRH antagonist stimulation protocol and assigned to the luteal-phase group, four had no embryos for transfer. Of the remaining 146 patients who received allocated intervention, one was excluded from analysis because of failure to follow correctly the protocol of luteal-phase examinations, and 145 terminated the study and were analysed (Figure 1B). Among the patients treated with the GnRH antagonist stimulation protocol and assigned to the placebo group, one was cancelled because of inadequate response to ovarian stimulation and four had no embryos for transfer. Of the remaining 145 patients who received allocated intervention, one was excluded from analysis because of failure to follow correctly the protocol of luteal-phase examinations, and 144 terminated the study and were analysed (Figure 1B). Effects of luteal-phase administration in the long ovarian stimulation protocol The patients in the luteal-phase and placebo groups did not differ in their basic demographical characteristics, and the features of their ovulation stimulation cycles were also comparable (Table I). The concentrations of E 2, determined on day 7 after ICSI in both groups, did not differ significantly (Table II), although there was a strong trend towards higher values in the group (P = 0.053). However, serum concentration of E 2, determined on day 15 after ICSI, and that of progesterone, determined on both days 7 and 15 after ICSI, were higher in the luteal-phase group as compared with the placebo (Table II). Moreover, the patients given 6 days after ICSI, who subsequently developed a clinical pregnancy, had a higher serum β-hcg concentration on day 15 after ICSI as compared with pregnant patients in the placebo group, and this difference was also evident when only those patients in whom a single gestational sac was subsequently detected were taken into account (Table II). With a similar number and morphology of embryos transferred, patients in the luteal-phase group had higher implantation and live birth rates than those in the placebo group, whereas the differences in the clinical pregnancy and ongoing pregnancy rates were not significant (Table III). There were 22 multiple births (21 twin and 1 triplet) in the group as compared with only five multiple births (4 twin and 1 triplet) in the placebo group. Using multivariate analysis, we observed that the female age and the number of oocytes recovered were independent predictors of
4 for luteal-phase support A Assessed for eligibility (n = 321) Excluded (n = 21) - Not meeting inclusion criteria (n = 13) - Refused to participate (n = 8) - Other reasons (n = 0) Randomized (n = 300) GnRHa Allocated to intervention (n = 150) - Received allocated intervention (n = 145) - Did not receive allocated intervention (n = 5) Allocated to intervention (n = 150) - Received allocated intervention (n = 143) - Did not receive allocated intervention (n = 7) - Lost to follow up (n = 1) - Discontinued intervention (n = 0) - Lost to follow up (n = 0) - Discontinued intervention (n = 0) Analysed (n = 141) - Excluded from analysis (n = 3) Analysed (n = 142) - Excluded from analysis (n = 1) B Assessed for eligibility (n = 318) Excluded (n = 18) - Not meeting inclusion criteria (n = 11) - Refused to participate (n = 7) - Other reasons (n = 0) Randomized (n = 300) GnRHa Allocated to intervention (n = 150) - Received allocated intervention (n = 146) - Did not receive allocated intervention (n = 4) Allocated to intervention (n = 150) - Received allocated intervention (n = 145) - Did not receive allocated intervention (n = 5) - Lost to follow up (n = 0) - Discontinued intervention (n = 0) - Lost to follow up (n = 0) - Discontinued intervention (n = 0) Analysed (n = 145) - Excluded from analysis (n = 1) Analysed (n = 144) - Excluded from analysis (n = 1) Figure 1. Patient flow through the randomized trial. (A) Patients with ovarian stimulation protocol using. (B) Patients with ovarian stimulation protocol using GnRH antagonist. 2575
5 J.Tesarik et al. Table I. Basic demographic and ovarian stimulation cycle characteristics of patients treated with the long ovarian stimulation protocol Characteristics Patient group a Age (years) 34.8 ± ± 1.7 BMI (kg m 2 ) 23.9 ± ± 1.9 Duration of FSH therapy (days) 11.8 ± ± 0.6 Total amount of FSH given (IU) 2488 ± ± 118 Total amount of HMG given (IU) 477 ± ± 34 Peak serum E 2 (pg ml 1 ) 1745 ± ± 190 Number of oocytes recovered b 12.4 ± ± 4.5 Values are mean ± SD. The differences between the two groups are not significant (P > 0.05). a Intention-to-treat group (n = 300). b Per stimulated cycle. Table II. characteristics of patients treated with the long GnRH agonist ovarian stimulation protocol implantation and ongoing pregnancy in both the and the placebo groups (data not shown). Effects of luteal-phase administration in the GnRH antagonist ovarian stimulation protocol The patients in the luteal-phase and placebo groups did not differ in their basic demographical characteristics, and the features of their ovulation stimulation cycles were also comparable (Table IV). However, the concentrations of E 2 and progesterone were higher in the luteal-phase group than in the placebo group, both on days 7 and 15 after ICSI (Table V). Moreover, the patients given 6 days after ICSI, who subsequently developed a clinical pregnancy, had a higher serum β-hcg concentration on day 15 after ICSI as compared with pregnant patients in the placebo group, and this difference was also evident when only those patients in whom a single gestational sac was subsequently detected were taken into account (Table V). With a similar number and morphology of embryos transferred, patients in the luteal-phase group had Characteristics Patient group a Table IV. Basic demographic and ovarian stimulation cycle characteristics of patients treated with the GnRH antagonist ovarian stimulation protocol Serum estradiol (pg ml 1 ) Day 7 after ICSI 432 ± ± 58 Day 15 after ICSI 480 ± 74 c 462 ± 71 Serum progesterone (ng ml 1 ) Day 7 after ICSI 44 ± 5 c 39 ± 5 Day 15 after ICSI 47 ± 7 c 43 ± 6 Serum HCG (IU l 1 ) Day 15 after ICSI In all conception cycles b 66 ± 8 c 42 ± 7 In singleton pregnancies 53 ± 6 c 34 ± 5 Values are mean ± SD. a Group of patients having terminated the study (n = 283). b Only cycles that resulted in a clinical pregnancy are included. c Significantly different from the placebo group (P < 0.05). Characteristics Patient group a Age (years) 31.3 ± ± 2.2 BMI (kg m 2 ) 23.8 ± ± 2.4 Duration of FSH therapy (days) 11.0 ± ± 0.6 Total amount of FSH given (IU) 2150 ± ± 172 Total amount of HMG given (IU) 282 ± ± 23 Peak serum E 2 (pg ml 1 ) 1931 ± ± 215 Number of oocytes recovered b 12.1 ± ± 4.2 Values are mean ± SD. The differences between the two groups are not significant (P > 0.05). a Intention-to-treat group (n = 300). b Per stimulated cycle. Table III. Clinical outcomes of patients treated with the long ovarian stimulation protocol Outcome variable Patient group a Mean ± SD (median). b Significantly different from the placebo group (P < 0.05). Intention to treat Transfer procedures Embryos transferred Embryos per transfer a 2.3 ± 0.5 (2.0) 2.3 ± 0.5 (2.0) Good-morphology 2.0 ± ± 0.5 (2.0) embryos per transfer a Clinical pregnancy rate Per embryo transfer 51.1% (72/141) 41.5% (59/142) Per intention to treat 48.0% (72/150) 39.3% (59/15 Clinical implantation rate 29.8% (97/325) b 18.2% (60/330) Ongoing pregnancy rate Per embryo transfer 46.8% (66/141) 38.0% (54/142) Per intention to treat 44.0% (66/150) 36.0% (54/150) Live birth rate 27.4% (89/325) b 18.2% (60/330) Table V. characteristics of patients treated with the GnRH antagonist ovarian stimulation protocol Characteristics Patient group a Values are mean ± SD. a Group of patients having terminated the study (n = 289). b Only cycle that resulted in a clinical pregnancy are included. c Significantly different from the placebo group (P < 0.05). Serum estradiol (pg ml 1 ) Day 7 after ICSI 405 ± 52 c 372 ± 48 Day 15 after ICSI 420 ± 56 c 408 ± 46 Serum progesterone (ng ml 1 ) Day 7 after ICSI 42 ± 8 c 29 ± 7 Day 15 after ICSI 48 ± 9 c 41 ± 7 Serum HCG (IU l 1 ) Day 15 after ICSI In all conception cycles b 64 ± 9 c 41 ± 7 In singleton pregnancies 50 ± 6 c 32 ±
6 for luteal-phase support Table VI. Clinical outcomes of patients treated with the GnRH antagonist ovarian stimulation protocol Outcome variable Patient group a Mean ± SD (median). b Significantly different from the placebo group (P < 0.05). Transfer procedures Embryos transferred Embryos per transfer a 2.2 ± 0.4 (2.0) 2.3 ± 0.5 (2.0) Good-morphology embryos 1.9 ± 0.4 (2.0) 2.0 ± 0.4 (2.0) per transfer Clinical pregnancy rate Per embryo transfer 47.6% (69/145) 37.5% (54/144) Per intention to treat 46.0% (69/150) 36.0% (54/150) Clinical implantation rate 27.1% (86/317) b 17.4% (57/328) Ongoing pregnancy rate Per embryo transfer 44.8% (65/145) b 31.9% (46/144) Per intention to treat 43.3% (65/150) b 30.7% (46/150) Live birth rate 25.2% (80/317) b 14.6% (48/3328) higher implantation, ongoing pregnancy and live birth rates than those in the placebo group (Table VI), and there was also a trend towards a higher clinical pregnancy rate in the GnRH agonist group (P = 0.083). There were 15 multiple births (all twins) in the group as compared with only two multiple births (both twins) in the placebo group. Using multivariate analysis, we observed that the female age and the number of oocytes recovered were independent predictors of implantation and ongoing pregnancy in both the and the placebo groups (data not shown). Discussion Several lines of evidence suggest that the luteal phase after embryo transfer is deficient in cycles stimulated with HMG or FSH, irrespectively of whether a (Macklon and Fauser, 2000; Pritts and Atwood, 2002) or a GnRH antagonist (Beckers et al., 2003; Kolibianakis et al., 2003) is used for the prevention of a premature LH surge. To solve this problem, most clinics use some form of luteal-phase support after embryo transfer. This can be done by stimulating progesterone secretion by the corpus luteum with exogenous HCG administration or by a direct supplementation of exogenous progesterone (reviewed in Pritts and Atwood, 2002). In this prospective randomized study, evaluating the effects of administered in a single dose 6 days after ICSI on luteal-phase characteristics and clinical outcomes, both HCG and progesterone supplementation were used in both the treatment and the placebo groups, in addition to oral E 2. Consequently, any effect of luteal-phase administration described in this study must be interpreted on the background of this basic luteal-phase support. The effects of luteal-phase administration were evaluated in the context of two different ovulation stimulation regimens, one using and the other GnRH antagonist. The results concerning ICSI clinical outcomes, namely clinical implantation and birth rates, confirm previous findings obtained in an oocyte donation model (Tesarik et al., 2004). The observed increase in clinical implantation rate in patients treated with in the luteal phase, as compared with the placebo group, indicates an increased risk of multiple pregnancies after this luteal-phase supplementation. Hence, it might be interesting to combine luteal-phase GnRH agonist administration with single embryo transfer. In addition, unlike patients in whom ovulation stimulation had been performed with the use of a long protocol, patients stimulated with the use of GnRH antagonist and receiving in the luteal phase had also a higher delivery rate and showed a trend towards a higher clinical pregnancy rate as compared with the corresponding placebo group. The relationship between the protocol of ovarian stimulation and the subsequent effects of luteal-phase administration of is not clear and remains an intriguing challenge for further research, namely in the context of the current efforts at optimization of the use of GnRH antagonists in ovarian stimulation (Fauser and Devroey, 2005). The fact that beneficial effects of luteal-phase on these variables was achieved here on the background of luteal-phase support with HCG, progesterone and E 2 supports the originally formulated hypothesis that exerts a direct beneficial effect on the implanting embryo (Tesarik et al., 2004). The hypothesis of a direct action of on the embryo (Tesarik et al., 2004) is further corroborated by the present observation of higher levels of serum β-hcg, both in the overall group of patients who achieved a pregnancy and after the exclusion of multiple pregnancies from the analysis, after luteal-phase administration of as compared with placebo. It was reported previously that GnRH increases serum HCG in pregnant women (Iwashita et al., 1993), presumably by acting on a placental GnRH receptor (Lin et al., 1995), and results in excessive binding of circulating GnRH by a yet-undefined GnRH-binding substance, possibly an auto-antibody reported in patients with repeated early pregnancy wastage (Siler-Khodr et al., 1997). However, the arguments in favour of a direct effect of on the embryo do not exclude other mechanisms of action acting in parallel. Unlike the situation in the oocyte donation model, the corpus luteum may have been another target of action in the present setting. In fact, an increase in serum concentrations of both E 2 and progesterone in the luteal phase of patients given 6 days after ICSI as compared with patients receiving placebo was observed in this study. These observations were made in both types of ovarian stimulation regimens employed in this study. The mechanism of action of on the corpus luteum remains a controversial issue. Early studies suggested that treatment in the luteal phase (one or two administrations of 500 μg of buserelin) may act as a luteolytic agent for contraceptive purposes (Lemay et al., 1982, 1983), supposedly due to GnRH receptor desensitization in gonadotroph cells. In fact, this may be true for certain doses of GnRH agonist, although the hypothesis of a contraceptive action of s has never been definitely confirmed, and attempts at inducing early abortion in women by huge doses of a superactive resulted in a failure (Skarin et al., 1982). More recently, a number of observational clinical studies 2577
7 J.Tesarik et al. reported the consequences of an inadvertent administration of in the luteal phase, and with only one exception (Herman et al., 1992), all agree in that luteal-phase administration does not compromise the continuation of pregnancy resulting from assisted reproduction attempts but rather seems to support implantation (Golan et al., 1990; Isherwood et al., 1990; Ron-El et al., 1990; Smitz et al., 1991; Jackson et al., 1992; Balasch et al., 1993; Elefant et al., 1993; Har-Toov et al., 1993; Weissman and Shoham, 1993; Wilshire et al., 1993; Young et al., 1993; Gartner et al., 1997). Moreover, a recent small randomized study suggested that low doses of (100 μg of buserelin) exert a stimulatory effect on the corpus luteum (Pirard et al., 2005). The present data strongly support this hypothesis. It is not known whether the increase in the synthesis of E 2 and progesterone in patients given in the luteal phase is mediated by pituitary hormones or results from a direct action of in the ovary. Our failure to detect a measurable increase in serum LH concentration 1 day after administration does not support a role for the pituitary in these events, but it must be reminded that a short LH peak, sufficient to produce this effect, may not be detected with the design of this study. If stimulates placental production of HCG, which is known to promote the secretion of vascular endothelial growth factor (VEGF), the main player in the development of OHSS (McClure et al., 1994; Neulen et al., 1995; Krasnow et al., 1996), a question arises about the safety of luteal-phase administration in patients at high risk of OHSS. Surprisingly, however, a recent study performed in an animal (rat) model has shown that administration during the luteal phase reduces the expression of VEGF and VEGF receptors, both at mrna and protein levels, and decreases vascular permeability in the hyperstimulated ovaries (Kitajima et al., 2004). Moreover, the continuation of GnRH agonist administration in -down-regulated IVF cycles has been shown to prevent the development of the early OHSS in at-risk patients in whom embryo transfer is not performed and all embryos are cryopreserved (Endo et al., 2002). The -induced increase in HCG production by the embryo at early stages of implantation is probably too low to affect significantly VEGF synthesis in extrauterine locations, and the decrease in the ovarian VEGF and VEGF receptor expression operated by (Kitajima et al., 2004) may be related to action on the pituitary ovarian axis, independent of its effect on the early embryo. In this study, we have not observed any case of severe OHSS requiring hospitalization. There is thus no a priori reason why GnRH agonist should be avoided as luteal-phase support in this category of patients, although caution is recommended until more complete information on the effects of luteal-phase administration at different levels of the reproductive system is available. Moreover, a GnRH receptor site was immunolocalized in murine endometrium (Murdoch, 1995), and a functional LH receptor has been detected in the human uterus (Reshef et al., 1990). A direct action of or induced LH in the uterine tissues can thus also be responsible for the observed luteal-phase effects In conclusion, the results of this prospective randomized study extend previous findings of a beneficial effect of GnRH agonist administration in the luteal phase on embryo implantation potential, obtained in an oocyte donation programme, to ovarian stimulation cycles using both and GnRH antagonist for prevention of premature LH surge. This effect was particularly evident in ovarian stimulation cycles using GnRH antagonist. Moreover, these data corroborate the hypothesis of a direct action of on the implanting embryo by demonstrating a stimulatory effect on β-hcg secretion, but they also suggest a direct or indirect positive effect on the corpus luteum function. These observations open the idea of a broader use of as a novel lutealphase support, possibly in combination with the conventionally employed HCG, E 2 and progesterone, especially in GnRH antagonist-using ovarian stimulation regimens. However, caution is needed as to eventual late-appearing health effects of this therapy on the offspring. The present data are likely to prompt further studies into the mechanism of action of GnRH agonist in the luteal phase. Pre-clinical studies are also needed to determine the optimal dose, time and frequency of GnRH agonist administration. References Balasch J, Martinez F, Jové I, Cabré L, Coroleu B, Barri PN and Vanrell JA (1993) Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod 8, Beckers ND, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E and Fauser BC (2003) Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropinreleasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 88, Elefant E, Biour B, Blumberg-Tick J, Roux C and Thomas F (1993) Administration of a gonadotropin-releasing hormone agonist during pregnancy: followup of 28 pregnancies exposed to triptoreline. Fertil Steril 63, Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, Azumaguchi A, Kamiya H and Kudo R (2002) Continuation of administration for 1 week, after hcg injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 17, Fauser BC and Devroey P (2005) Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 83, Gartner B, Moreno C, Marinaro A, Remohi J, Simon C and Pellicer A (1997) Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod 12, Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y and Caspi E (1990) Fetal outcome following inadvertent administration of long-acting D-Trp 6 LH-RH microcapsules during pregnancy: a case report. Hum Reprod 5, Har-Toov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR and Lessing JB (1993) Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril 59, Herman A, Ron-El R, Golan A, Nachum H, Soffer Y and Caspi E (1992) Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod 7, Isherwood PJ, Ibrahim ZA, Matson PL, Morroll DR, Burslem RW and Lieberman BA (1990) Endocrine changes in women conceiving during treatment with a LHRH agonist. Hum Reprod 5, Iwashita M, Kudo Y, Shinozaki Y and Takeda Y (1993) Gonadotropin-releasing hormone increases serum human chorionic gonadotropin in pregnant women. Endocr J 40,
8 for luteal-phase support Jackson AE, Curtis P, Amso N and Shaw RW (1992) Exposure to LHRH agonist in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation. Hum Reprod 7, Kitajima Y, Endo T, Manase K, Nishikawa A, Shibuya M and Kudo R (2004) Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril 81 (Suppl. 1), Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC and Devroey P (2003) Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 80, Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ and Yeo KT (1996) Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 65, Lemay A, Faure N and Labrie F (1982) Sensitivity of pituitary and corpus luteum responses to single intranasal administration of buserelin in normal women. Fertil Steril 37, Lemay A, Faure N, Labrie F and Fazekas AT (1983) Gonadotrophin and corpus luteum responses to two successive intranasal doses of a luteinising hormone-releasing hormone agonist at different days after the mid-cycle luteinising hormone surge. Fertil Steril 39, Lin L, Roberts VJ and Yen S (1995) Expression of human gonadotropinreleasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 80, Macklon NS and Fauser BC (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl 55, McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT and Robertson DM (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344, Murdoch WJ (1995) Immunolocalization of a GnRH receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 282, Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D and Breckwoldt M (1995) Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80, Pirard C, Donnez J and Loumaye E (2005) as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 20, Pritts EA and Atwood AK (2002) Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17, Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N and Luborsky JL (1990) The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes and deciduas. J Clin Endocrinol Metab 70, Ron-El R, Golan A, Herman A, Raziel A, Soffer Y and Caspi E (1990) Midluteal gonadotropin-releasing hormone analog administration in early pregnancy. Fertil Steril 53, Siler-Khodr TM, Smikle CB, Sorem KA, Grayson MA, Spencer DK, Yoder BK and Khodr GS (1997) Effect of excessive GnRH-binding substance on circulating maternal hcg in human pregnancy. Early Pregnancy 3, Skarin G, Nillius SJ and Wide L (1982) Failure to induce early abortion by huge doses of a superactive LHRH agonist in women. Contraception 26, Smitz J, Camus M, Devroey P, Bollen N, Tournaye H and Van Steirteghem AC (1991) The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 6, Tesarik J and Greco E (1999) The probability of abnormal preimplantation development can be predicted by a single static observation on pronuclear stage morphology. Hum Reprod 14, Tesarik J and Mendoza C (2002) Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 17, Tesarik J, Junca AM, Hazout A, Aubriot FX, Nathan C, Cohen-Bacrie P and Dumont-Hassan M (2000) Embryos with high implantation potential after intracytoplasmic sperm injection can be recognized by a simple, non-invasive examination of pronuclear morphology. Hum Reprod 15, Tesarik J, Hazout A and Mendoza C (2004) Enhancement of embryo developmental potential by a single administration of at the time of implantation. Hum Reprod 19, Weissman A and Shoham Z (1993) Favourable pregnancy outcome after administration of a long-acting gonadotropin-releasing hormone agonist in the mid-luteal phase. Hum Reprod 8, Wilshire GB, Emmi AM, Gagliardi CC and Weiss G (1993) Gonadotropinreleasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 60, Young DC, Snabes MC and Poindexter AN (1993) exposure during the first trimester of pregnancy. Obstet Gynecol 81, Submitted on November 26, 2005; resubmitted on February 20, 2006, April 16, 2006; accepted on April 21,
GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study
Human Reproduction Vol.21, No.7 pp. 1894 1900, 2006 Advance Access publication March 23, 2006. doi:10.1093/humrep/del072 GnRH agonist as luteal phase support in assisted reproduction technique cycles:
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationAssisted Reproduction Unit, American Hospital of Istanbul, Guzelbahce Sokak No. 20, Nisantasi, Istanbul 34365, Turkey
Human Reproduction Vol.23, No.3 pp. 668 673, 2008 Advance Access publication on January 12, 2008 doi:10.1093/humrep/dem421 GnRH agonist protocol administration in the luteal phase in ICSI ET cycles stimulated
More informationKey words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct
Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationOriginal Article. J Reprod Infertil. 2015;16(2):96-101
Original Article Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Outcome of ICSI-ET Cycles in Women with Previous History of IVF/ICSI Failure: A Randomized Controlled Trial Simin
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationAbstract. Introduction. Materials and methods. Patients and methods
RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationPediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain
Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study María-José Escribá, Ph.D.,
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationE.G. Papanikolaou 1,2,3, *, G. Pados 1,3, G. Grimbizis 1,3, E. Bili 1,3, L. Kyriazi 3, N.P. Polyzos 4,P.Humaidan 5,H.Tournaye 4,andB.
Human Reproduction, Vol.27, No.6 pp. 1822 1828, 2012 Advanced Access publication on March 14, 2012 doi:10.1093/humrep/des066 ORIGINAL ARTICLE Reproductive endocrinology GnRH-agonist versus GnRH-antagonist
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationUse of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?
Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER
*40639* 40639 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IVF WITH EMBRYO TRANSFER I have requested treatment by the physicians and (Print Patient s name) staff of the Women & Infants Fertility
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationIVF Patient Information
What is IVF? IVF (In Vitro Fertilisation) is a treatment by which fertilisation of eggs by sperm takes place outside the body in a dish in an IVF laboratory. An ovary has a pool of immature eggs. In a
More informationORIGINAL ARTICLE Early pregnancy
Human Reproduction, Vol.26, No.5 pp. 1020 1024, 2011 Advanced Access publication on February 4, 2011 doi:10.1093/humrep/der012 ORIGINAL ARTICLE Early pregnancy Does cessation of progesterone supplementation
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationHum. Reprod. Advance Access published March 9, 2010
Human Reproduction, Vol.00, No.0 pp. 1 6, 2010 doi:10.1093/humrep/deq059 Hum. Reprod. Advance Access published March 9, 2010 ORIGINAL ARTICLE Infertility Avoidance of weekend oocyte retrievals during GnRH
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationComparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation
Basrah Journal Of Surgery COMPARISON OF GNRH AGONIST WITH LOW-DOSE URINARY HCG FOR THE INDUCTION OF FINAL OOCYTE MATURATION IN HIGH-RISK PATIENTS UNDERGOING INTRACYTOPLASMIC SPERM INJECTION-EMBRYO TRANSFER
More informationShould we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationJournal of Experimental & Clinical Assisted Reproduction 2007, 4:1
Journal of Experimental & Clinical Assisted Reproduction BioMed Central Hypothesis Serum estradiol/progesterone ratio on day of embryo transfer may predict reproductive outcome following controlled ovarian
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does
More informationIn vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day of HCG injection: An RCT
Int J Reprod BioMed Vol. 15. No. 12. pp: 757-762, December 2017 Original article In vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.
*40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print
More informationStudy on Several Factors Involved in IVF-ET of Human Beings
Study on Several Factors Involved in IVF-ET of Human Beings Lei X 1, Zhuoran W 1, Bin L 1, Huiming L 1, Hongxiu Z 1, Yajuan Z 1, Yingbo Q 1, Guixue Z 2 1 The First Clinical College of Harbin Medical University,
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationElonva (corifollitropin alfa): A simplified, patientfocused
Product Monograph (corifollitropin alfa): A simplified, patientfocused approach to controlled ovarian stimulation TABLE OF CONTENTS (corifollitropin alfa): A simplified, patientfocused approach to controlled
More informationThe Comparison of Clinical Outcomes between GnRH Agonist Long Protocol and GnRH Antagonist Short Protocol in Oocyte Donation Cycles
: 30 1 2003 Kor J Fertil Steril, Vol 30, No 1, 2003, 3 The Comparison of Clinical Outcomes between GnRH Agonist Long Protocol and GnRH Antagonist Short Protocol in Oocyte Donation Cycles Jeong Ho Rhee,
More informationThe psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy
Human Reproduction Vol.22, No.9 pp. 2554 2558, 2007 Advance Access publication on June 23, 2007 doi:10.1093/humrep/dem171 The psychological impact of IVF failure after two or more cycles of IVF with a
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationPaternal effects acting during the first cell cycle of human preimplantation development after ICSI
Human Reproduction Vol.17, No.1 pp. 184 189, 2002 Paternal effects acting during the first cell cycle of human preimplantation development after ICSI Jan Tesarik 1,2,5, Carmen Mendoza 2,3 and Ermanno Greco
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationEHY Ng, WSB Yeung, PC Ho. Introduction
Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study EHY Ng, WSB Yeung, PC Ho
More informationCorifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 RESEARCH Open Access Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationOVULATION INDUCTION. Ori Nevo, M.D., a Talia Eldar-Geva, M.D., Ph.D., b Shahar Kol, M.D., a and Joseph Itskovitz-Eldor, M.D., D.Sc.
FERTILITY AND STERILITY VOL. 79, NO. 5, MAY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. OVULATION INDUCTION Lower levels
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationAbstract. Introduction. RBMOnline - Vol 7. No Reproductive BioMedicine Online; on web 16 July 2003
RBMOnline - Vol 7. No 3. 301 308 Reproductive BioMedicine Online; www.rbmonline.com/article/903 on web 16 July 2003 Article Comparable effectiveness using flexible singledose GnRH antagonist (cetrorelix)
More informationMaria A. Manzanares, M.D., Jose Lui Gomez-Palomares, M.D., Elisabetta Ricciarelli, M.D., and Eleuterio R. Hernandez, M.D., Ph.D.
Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationAsimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2
Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationLUTEAL PHASE DEFICIT AND PROGESTERONE SUPPLEMENTATION IN ART
LUTEAL PHASE DEFICIT AND PROGESTERONE SUPPLEMENTATION IN ART 19 Djuro Macut *, Lidija Tulić ** and Ivan Tulić *** LUTEAL PHASE DEFICIT AND PROGESTERONE SUPPLEMENTATION IN ART Abstract: Luteal phase deficit
More informationRafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationA comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nadkarni PK et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):617-621 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationPredictive value of embryo grading for embryos with known outcomes
Predictive value of embryo grading for embryos with known outcomes Vanessa N. Weitzman, M.D., Jennifer Schnee-Riesz, M.D., Claudio Benadiva, M.D., John Nulsen, M.D., Linda Siano, M.S., and Donald Maier,
More informationIntroduction. ORIGINAL ARTICLE Infertility
Human Reproduction, Vol.25, No.3 pp. 683 689, 2010 Advanced Access publication on December 15, 2009 doi:10.1093/humrep/dep436 ORIGINAL ARTICLE Infertility Flexible GnRH antagonist protocol versus GnRH
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationInternational Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison
More informationOriginal Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
Int J Clin Exp Med 2016;9(7):14677-14683 www.ijcem.com /ISSN:1940-5901/IJCEM0026636 Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI
More informationProfound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF
Human Reproduction Vol.19, No.11 pp. 2490 2496, 2004 Advance Access publication August 19, 2004 doi:10.1093/humrep/deh471 Profound LH suppression after GnRH antagonist administration is associated with
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationEmbryo Selection after IVF
Embryo Selection after IVF Embryo Selection after IVF Many of human embryos produced after in vitro fertilization carry abnormal chromosomes. Placing a chromosomally normal embryo (s) into a normal uterus
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationIranian Journal of Reproductive Medicine Vol. 2. No.1 pp 29-33, 2004
Efficacy of Low Dose, Long-acting Gonadotropin Releasing Hormone Analogues (GnRH-a) Compared with Daily Injections of Short-acting GnRH-a in ART Cycles Robabeh Taheripanah M.D. 1, Mohammad A. Karimzadeh
More informationTriggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial
Gynecological Endocrinology, January 2009; 25(1): 60 66 HCG Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial ANNA GALINDO, DANIEL BODRI,
More informationThe Human Menstrual Cycle
The Human Menstrual Cycle Name: The female human s menstrual cycle is broken into two phases: the Follicular Phase and the Luteal Phase. These two phases are separated by an event called ovulation. (1)
More informationHongjuan Ye 1*, Hui Tian 1, Wen He 2, Qifeng Lyu 2, Yanping Kuang 2, Qiuju Chen 2* and Lihua Sun 1*
Ye et al. Reproductive Biology and Endocrinology (2018) 16:53 https://doi.org/10.1186/s12958-018-0373-7 RESEARCH Open Access Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0159 2013 Sep.; 24(3):159-172 E-mail: randc_journal@163.com Comparison of the Effects and Safety of Mild Ovarian Stimulation
More informationThe outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology
Human Reproduction vol.14 no.1 pp.167 171, 1999 The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology Lawrence Engmann 1,2,5, Noreen Maconochie
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More information